# Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

> **NCT00871923** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 44 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Brain Cancer

## Interventions

- **DRUG:** Tarceva (Erlotinib hydrochloride)
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT00871923
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-26
- **Primary completion:** 2019-12-04
- **Final completion:** 2019-12-04
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2021-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871923, "Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00871923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*